about
Gliomatosis cerebri: a review.Antiangiogenic therapy of brain tumors: the role of bevacizumab.Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept.Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective studyBevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).Anti-angiogenic approaches to malignant gliomas.Safety of bevacizumab in patients with malignant gliomas: a systematic review.Pharmacologic therapies for malignant glioma: a guide for clinicians.Is there a Role for Bevacizumab in Non-Glial Tumors?Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas.Distinctive pathological and clinical features of lung carcinoids with high proliferation index.Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps.Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.O9.09EFFICACY AND TOLERABILITY OF LACOSAMIDE IN PATIENTS WITH GLIOMA: A PROSPECTIVE STUDY.PRE-OPERATIVE CHEMOTHERAPY AS A NEW STRATEGY OF TREATMENT FOR LOW GRADE GLIOMAS IN ELOQUENT AREAS.TEMOZOLOMIDE FOR RECURRENT INTRACRANIAL EPENDYMOMA OF THE ADULT: PATTERNS OF RESPONSE, SURVIVAL AND CORRELATIONS WITH MGMT PROMOTER METHYLATION.P06.08SYSTEMIC TREATMENT OF MENINGIOMAS: IS THERE A ROLE FOR LONG-ACTING SOMATOSTATIN?P12.04GLIOMATOSIS CEREBRI: IS THERE A ROLE FOR SURGERY OTHER THAN BIOPSY?P15.10COGNITIVE AND FUNCTIONAL STATUS OF PATIENTS AND QUALITY OF LIFE OF CAREGIVERS: A PROSPECTIVE STUDY IN A COHORT OF RECURRENT GLIOBLASTOMAS.O8.01PRE-OPERATIVE CHEMOTHERAPY AS A NEW STRATEGY IN TREATING LOW GRADE GLIOMAS IN ELOQUENT AREAS.O10.06A PHASE II STUDY OF AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY) ON BEVACIZUMAB AND FOTEMUSTINE FOR RECURRENT GLIOBLASTOMA: OUTCOME, PATTERNS OF RELAPSE AND SALVAGE TREATMENTS.Molecular alterations of neuroendocrine tumours of the lung.Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?The role of the AR/ER ratio in ER-positive breast cancer patients.Mesenchymal/radioresistant traits in granular astrocytomas: evidence from a combined clinical and molecular approach.A 68-Year-Old Woman with A Left Orbital and Temporal Mass.Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide.Expression analysis of High-mobility group box-1 (HMGB1) in histologic samples of malignant pleural mesothelioma.Mitochondrial DNA "common deletion" in post-fine needle aspiration infarcted oncocytic thyroid tumors.Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic"?Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices.Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations.Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review.MS-22NEOPLASTIC MENINGITIS FROM EPENDYMOMAS OF THE ADULT: A RETROSPECTIVE ANALYSIS.The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human GliomasPathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small seriesChildhood-onset multiple self-injurious behaviors in Gilles de la Tourette syndromePrognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and OutcomeTERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk.
P50
Q30726280-031AC43E-2AA1-4CEC-9AEF-2156530CE1B7Q30737224-9146BF81-2889-48AC-91DA-A6F8CA95EE68Q33778007-69611182-8138-4202-9447-3BBB7189F6DDQ37312684-9041F429-A858-4F38-A8F9-DD550DE3B710Q37526275-F9FB6848-9E71-4028-9352-8145BFFA75FBQ37974235-2F3BC568-7B25-4E84-8D48-08FE8C1CB861Q38166676-966DDCF2-20A5-4AAB-9C74-1BA630FE72D1Q38268897-7FAC4B96-42DB-4EB8-90F4-3AB32B01D8A6Q38390921-0940229E-16CE-49FB-9726-E11E5BA4D1B0Q38715289-14F73AFF-2DD9-4E61-96AC-BF14B1BB35D0Q38718054-1E680029-6223-4896-9BE4-0379215B58D2Q40595545-A7C48E18-FDCE-4007-97C1-AEA0026462DCQ40815536-79F4C0CB-FD3D-408E-858B-79446008C00DQ45831690-6E91D47F-057F-435A-812D-FE6B127AA740Q46226203-A6A414E5-256D-48EB-A081-A6A98017E487Q46226498-71AF79F4-25B9-430D-982C-5C30B5BF2277Q46881642-6C4E2475-0347-48FA-9930-34F89367FBF0Q46882781-06B3CA0C-99C7-4E06-9CCB-3958141C5156Q46883752-ABC4254A-BDBB-42E3-8B18-2708EE440F81Q46886519-CF953403-D885-4F42-BB2F-CFD835F306D3Q46886939-3E973400-6A95-40DD-8D3D-CD79BD49A9B2Q47312955-882128B9-67E9-403A-8DC2-60D15A02FE33Q47361459-D6C6978C-EF24-45A6-9FAD-5B88468E1AB7Q47554058-5F5F747B-093B-40D0-A9B8-55EC64B96E00Q47885282-2B169018-65F6-48CF-AB12-40F1664EE9A6Q47902938-C0D94ABE-9B47-49CA-BE2D-6B1603C16963Q48564051-07E188F1-4613-457B-8D09-9FA03DEE014EQ49884162-F030F721-E754-4860-A69B-4633C08A92B2Q50270058-D580EC7A-9B56-4690-9A51-F3653AEEE7C4Q50324439-624FB12C-1542-462C-9B98-30C9B28860F2Q53280824-7DE92A8D-312E-4ADE-89FA-E6845EDAD28CQ54976713-1CB13CFF-673C-487A-98D4-40497381E104Q55327976-7B955C7A-9848-49D5-B36B-F3E854ACB9F6Q55457030-597DEC48-A4CE-422A-8FF7-358C409130E3Q55630269-BCFECEA9-20F0-427A-9335-B37FC34C8730Q58745277-B9392CC3-0ABB-491B-A7B2-6682BDED2140Q58763660-17E931CB-6247-4B97-8CF9-94117E5DA237Q60624378-0EE56DF6-0149-45B0-BCC4-DA4B4079428FQ64255711-005EC200-B5C2-4420-93BB-84A2AC06D6CCQ64935865-B59A29EF-99AF-42E3-8969-7BAA74B883AD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luca Bertero
@ast
Luca Bertero
@en
Luca Bertero
@es
Luca Bertero
@nl
Luca Bertero
@sl
type
label
Luca Bertero
@ast
Luca Bertero
@en
Luca Bertero
@es
Luca Bertero
@nl
Luca Bertero
@sl
prefLabel
Luca Bertero
@ast
Luca Bertero
@en
Luca Bertero
@es
Luca Bertero
@nl
Luca Bertero
@sl
P106
P1153
55980277000
P31
P496
0000-0001-9887-7668